Studies and Evidence

Evidence in the scientific literature primarily relates to sporadic FeNO measurements in the doctor's office. What has not yet been investigated to the same extent is the additional benefit of FeNO home monitoring performed by patients. In this regard, the FeNO@home study provides new, groundbreaking insights. It was conducted as a multicenter study in Germany and Italy, enrolling asthma patients of varying severity. Furthermore, the study tested how the Vivatmo me patient device from Bosch performs in everyday use. Starting with the first presentations at the ERS Congress 2024, the results will now gradually be published in renowned journals.

Bosch Healthcare provided its Vivatmo me home measurement device and the Vivatmo app asthma diary for the FeNO@home study. Although final results are pending, it is becoming apparent that FeNO home monitoring can

• improve the quantity and information value of patient data
• and significantly reduce study coordination efforts.

Although patients need to visit the study centers less frequently, they contribute more FeNO values over time and provide additional contextual information via the companion app. The cost-effective enhancement of the patient dataset can be valuable in research as well as help specialists to improve asthma management.